TITLE:
Survival of Patients with Small-Cell Lung Cancer Treated at Tertiary Hospitals in the East of Thailand, 2007-2016: A Retrospective Study
AUTHORS:
Sitthi Sukauichai, Chokaew Tovanabutra, Thapana Tangchewinsirikul, Sirentra Wanglikitkoon, Kittisak Chomprasert, Teerayuth Namkanitsorn, Passakorn Wanchaijiraboon, Annop Kittiwarawut
KEYWORDS:
Survival, Small Cell Lung Cancer, Tertiary Hospitals, Thailand
JOURNAL NAME:
Advances in Lung Cancer,
Vol.8 No.1,
March
31,
2019
ABSTRACT: Objective:The objective of the study was to determine the survival of patientswith small-cell lung cancer treated at tertiary hospitals in the East ofThailand. Materials and methods:The researchers conducted this retrospectivestudy by reviewing medical records of patients with small-cell lung cancertreated at Chonburi Cancer Hospital and Prapokklao Hospital from January2007 to December 2016 and monitored via follow-up until December2018. Results:This study enrolled 54 patients with a median follow-up timeof 8.5 months. The median age of patients was 63 years old. Most patientswere male (83.3%) and had a history of smoking (90.7%), and 31.4% hadclinical superior vena cava obstruction at initial treatment. The Eastern CooperativeOncology Group performance status 0-1 was noted for 61.1% of thestudy population. Median survival time of patients with limited-stage and extensive-stage small cell lung cancer who received systemic chemotherapyand/or radiotherapy was 17.01 months (95% CI, 12.01 - 22.01) and 8.14months (95% CI, 7.19 - 9.10), respectively, and that of patients receivingsupportive care was 2.3 months (95% CI, 0.75 - 4.03). However, the mediansurvival time of patients with extensive-stage small-cell lung cancer receivingonly palliative chemotherapy was 5.9 months (95% CI, 0.32 - 17.51). Conclusions:The median survival time of patients with limited-stage small-cell lungcancer treated in the East of Thailand was comparable to those of landmarkstudies; however, the survival of patients with extensive-stage small-cell lungcancer was shorter than those of Phase III trials. A multidisciplinary team wasnecessary to improve the quality of patient care.